These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26730193)

  • 1. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study.
    Li H; Turkoz I; Zhang F
    Neuropsychiatr Dis Treat; 2016; 12():15-24. PubMed ID: 26730193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.
    Li H; Li Y; Feng Y; Zhuo J; Turkoz I; Mathews M; Tan W
    Neuropsychiatr Dis Treat; 2018; 14():1107-1117. PubMed ID: 29731633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia.
    Takahashi N; Takahashi M; Saito T; Iizumi M; Saito Y; Shimizu H; Matsumura T
    Neuropsychiatr Dis Treat; 2013; 9():1889-98. PubMed ID: 24353421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
    Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study.
    Zhang H; Li H; Liu Y; Wu C; Wu Q; Nuamah I; Shi J; Xie S; Wang G; Gopal S
    Neuropsychiatr Dis Treat; 2016; 12():69-77. PubMed ID: 26811679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.
    Si T; Zhang K; Tang J; Fang M; Li K; Zhuo J; Feng Y
    Neuropsychiatr Dis Treat; 2015; 11():1483-92. PubMed ID: 26150719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.
    Zhang F; Si T; Chiou CF; Harris AW; Kim CY; Jahagirdar P; Ascher S
    Neuropsychiatr Dis Treat; 2015; 11():657-68. PubMed ID: 25792835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.
    Zhao J; Li L; Shi J; Li Y; Xu X; Li K; Zhang L; Cai S; Feng Y; Zhuo J; Liu W; Lu H
    Neuropsychiatr Dis Treat; 2017; 13():2045-2056. PubMed ID: 28814873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability.
    Gattaz WF; Saracco-Alvarez R; Daltio CS; Van de Bilt MT; Ortegón JJ; Villaseñor-Bayardo SJ; Louzã M; Elkis H; Soares B; Cabrera Jaramillo P; Lawson F; Díaz-Galvis L
    Neuropsychiatr Dis Treat; 2020; 16():2063-2072. PubMed ID: 32982245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
    Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.
    Alphs L; Bossie CA; Sliwa JK; Ma YW; Turner N
    Ann Gen Psychiatry; 2011 Apr; 10(1):12. PubMed ID: 21481243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study.
    Savitz A; Lane R; Nuamah I; Singh J; Hough D; Gopal S
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):548-57. PubMed ID: 26218669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia.
    Garcia-Portilla MP; Llorca PM; Maina G; Bozikas VP; Devrimci-Ozguven H; Kim SW; Bergmans P; Usankova I; Pungor K
    Ther Adv Psychopharmacol; 2020; 10():2045125320926347. PubMed ID: 32518617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.